For research use only. Not for therapeutic Use.
LHC-165 is a TLR7 agonist. LHC-165 has potential to used in study of solid tumors[1][2].
| Catalog Number | I019385 |
| CAS Number | 1258595-14-0 |
| Synonyms | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
| Molecular Formula | C29H32F2N3O7P |
| Purity | ≥95% |
| InChI | InChI=1S/C29H32F2N3O7P/c1-18-14-22(41-13-12-40-11-10-29(30,31)42(37,38)39)7-6-21(18)5-2-20-15-24-23-8-3-19(4-9-26(35)36)16-25(23)34-28(32)27(24)33-17-20/h3,6-8,14-17H,2,4-5,9-13H2,1H3,(H2,32,34)(H,35,36)(H2,37,38,39) |
| InChIKey | SDLWKRZBLTZSEL-UHFFFAOYSA-N |
| SMILES | CC1=C(C=CC(=C1)OCCOCCC(F)(F)P(=O)(O)O)CCC2=CC3=C4C=CC(=CC4=NC(=C3N=C2)N)CCC(=O)O |
| Reference | [1]. Carole Bourquin, et al. Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists. Pharmacological Research. 2019 Mar. [2]. LHC165. |
